氯沙坦改善呼吸疾病或缺氧相关肺动脉高压的研究

目的研究口服氯沙坦治疗,对呼吸疾病或缺氧相关的肺动脉高压的影响。方法将入选的呼吸疾病或缺氧相关的肺动脉高压,心功能Ⅲ-Ⅳ级的入院患者120例随机分为常规治疗组和氯沙坦组。常规治疗组给予抗感染、平喘及对症支持治疗;氯沙坦组在常规治疗基础上加用氯沙坦钾片50mg每日,口服。所有患者治疗前后均检查心脏超声、肺功能及动脉血气。随访观察12周。结果两组患者治疗后平均肺动脉压、PaCO2均较治疗前下降,差别有统计学意义(P<0.05);FEV1%与PaO2均较治疗前升高,差别有统计学意义。氯沙坦组治疗后mPAP叫常规治疗组下降,差别有统计学意义(P<0.05)。两组均未出现明显药物不良反应。结论氯沙坦能够降低呼吸疾病或缺氧相关的肺动脉高压,并对呼吸功能无不良影响。

The Study of Losartan Improved Respiratory Diseases or Hypoxic Pulmonary Hypertension

Objective To evaluate efficacy of losartan in combined treatment of secondary pulmonary hypertension in patients with respiratory diseases or hypoxia.Methods Will be selected respiratory diseases or hypoxic pulmonary hypertension,heart function Ⅲ-Ⅳ class hospitalized patients 120 cases were randomly divided into conventional treatment group and losartan group.Conventional treatment group was given anti-infective,anti-asthmatic and symptomatic and supportive treatment;losartan group on conventional therapy plus losartan potassium tablets 50mg daily,orally.All patients before and after treatment to check echocardiography,pulmonary function and arterial blood gas.Were followed up for 12 weeks.Results After treatment,mean pulmonary artery pressure,PaCO2 compared with those before treatment,the difference was statistically significant（P 0.05）;FEV1% and increased PaO2 compared with those before treatment,the difference was statistically significant.MPAP losartan group after treatment,called the decline in the conventional treatment group,the difference was statistically significant（P 0.05）.The two groups were not significantly adverse drug reactions.Conclusion Losartan can reduce respiratory diseases or hypoxic pulmonary hypertension,and no adverse effects on respiratory function.